Document Detail


Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjogren's syndrome treated with rituximab.
MedLine Citation:
PMID:  22258489     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVE: To evaluate the responsiveness of the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) and EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) in patients with primary Sjögren's syndrome (pSS) treated with rituximab.METHODS: Twenty-eight patients with pSS treated with rituximab (1000 mg) infusions on days 1 and 15 were included in the study. Data were collected prospectively at baseline and 16, 24, 36, 48 and 60 weeks after treatment. Internal responsiveness was assessed using standardised response means (SRM) and effect sizes (ES). SRM and ES <0.5, 0.5-0.8 and >0.8 were interpreted as small, moderate and large, respectively. External responsiveness was assessed using Spearman correlation coefficients.RESULTS: Median (range) ESSPRI and ESSDAI scores at baseline were 6.7 (0.3-9.0) and 8 (2-18), respectively. Both indices improved significantly after treatment. SRM and ES values for ESSPRI and ESSDAI were ≥0.8 at week 16 and decreased afterwards, and were larger for ESSDAI than for ESSPRI. SRM and ES values for patient's and physician's global disease activity (GDA) and rheumatoid factor broadly followed the pattern of those of ESSPRI and ESSDAI. SRM and ES for stimulated whole salivary flow were small at all time points. At baseline and for most change scores, moderate to good correlations were found between ESSPRI and patient's GDA and between ESSDAI and physician's GDA. Poor association was found between ESSPRI and ESSDAI.CONCLUSIONS: ESSPRI and ESSDAI are sensitive measures of change in disease activity after therapeutic intervention, which supports the usefulness of these indices for future clinical trials in patients with pSS. The responsiveness of ESSDAI was greater than that of ESSPRI.
Authors:
P M Meiners; S Arends; E Brouwer; F K L Spijkervet; A Vissink; H Bootsma
Related Documents :
21419029 - Guillain barre syndrome in a family: a case report of four siblings.
21819519 - Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrom...
22171639 - Getting to the bottom of autism spectrum and related disorders: mbd5 as a key contributor.
21772869 - The metabolic syndrome in survivors of childhood acute lymphoblastic leukemia in isfaha...
21955869 - Young woman with branchio-oto-renal syndrome and a novel mutation in the eya-1 gene.
22178199 - Primary biliary cirrhosis and sjögren's syndrome: autoimmune epithelitis.
23046529 - Sweet's syndrome: a revisit for hematologists and oncologists.
22920009 - Orthostatic intolerance: postural orthostatic tachycardia syndrome with overlapping vas...
20409529 - Ogilvie transition to colonic perforation.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-1-17
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  -     ISSN:  1468-2060     ISO Abbreviation:  -     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-1-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
1Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Quantification of circulating endothelial progenitor cells in systemic sclerosis: a direct compariso...
Next Document:  Combination of IL-17 and TNF? induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype...